Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More
The Big Market Report Take
This biotech specializing in endocrine therapies reported a notable insider sale as it advances clinical-stage drug candidates.
Related Guides
Not financial advice. The Big Market Report aggregates news for informational purposes only. Nothing on this site constitutes investment advice. Equities and other securities are subject to market risk. Always do your own research and consult a qualified financial advisor before making any investment decisions. Full disclaimer →
Never miss a story
More from this section
- Mineros S.A. (MNSAF) Shareholder/Analyst Call TranscriptSeeking Alpha30m ago
AXT's CEO Sold Shares Worth $1.4 Million. Is Now the Time to Sell or Buy the Stock?The Motley Fool52m ago
Carnival Gets Hit By the Iran War. Can the Cruise Stock Bounce Back?The Motley Fool1h ago- Consumer Sentiment Plunges 6% Amid Energy Price Spikes And Market VolatilitySeeking Alpha1h ago